HCW BIOLOGICS INC
HCWBNASDAQTrading Snapshot
- Day Range
- $3.14 – $3.20
- 52-Week Range
- $1.50 – $44.10
- Volume
- $3.05B
- Avg Volume
- $2.15B
- Shares Outstanding
- 1.6M
- Next Earnings
- Sep 7, 2026
Fundamentals Snapshot
- Annual Revenue
- $54,232
- Last Q Revenue
- $7M
- P/E Ratio
- —
- P/S Ratio
- 0.8x
- EPS (TTM)
- $-8.07
- Dividend Yield
- —
Why Investors Own HCWB
- ✓High-growth profile — revenue up +58.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 63% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About HCW BIOLOGICS INC
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
HCW Biologics Prices $1.6M Private Placement Of 618,682 Units At A Price Of $2.5849/Unit
HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer
HCW Biologics Requests For Type B Meeting With FDA To Discuss Development, Regulatory Path For Its HCW11-018b Candidate To Treat Solid Tumors
HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Advanced Biomed (NASDAQ:ADVB) shares rose 24.1% to $6.24 during Monday's pre-market session. The market value of their outstanding shares is at $8.2 million. Barinthus Biotherapeutics (NASDAQ:BRNS) shares